Over a hundred out-licensors from different regions, company sizes and asset types share their perspectives about partnering and reveal what makes a deal attractive and what defines a successful partnership.
The Biotech Perspective 2022
Connecting the dots of biotech partnering
Priorities, strategies and needs
The balance of power in biopharma is shifting and there's a significant gap between
out-licensor expectations and in-licensor offers.
Pain points and deal-breakers
With venture capital competing with pharma for the most innovative life science, knowing
precisely what biotechs want can be the difference between inking a deal and missing out
altogether.
Partner of Choice and pharma ratings
In this exclusive report more than a hundred biotechs rank the world's largest pharma
companies for the quality of their partnering experience.
The digital revolution has not occured, yet
A shared vision for better biopharma partnering is being explored for the first time. This vision, labeled as the next generation of partnering, or Partnering 2030, is digital, data driven, and agile.
An influx of capital, increase in business acumen, and new deal options have provoked a power shift across the partnering landscape. Big pharma is facing fierce competition to identify and partner with the most innovative science. Heads of M&A and BD departments from top pharma companies have expressed similar pain points and needs, all pointing to the vision described.
What does it mean to be a Partner of Choice?
On the other side, out-licensors' priorities, needs, and expectations have been explored
in this exclusive report.
More than 100 biotechs of various sizes, from different
regions, and with different assets types and in different phases of development reveal
what makes a deal attractive and what defines a successful partnership.